ERBB2 and neoplasm: Schrock et al. and Takegawa et al. demonstrated that HER2 mutations and alterations are also detectable in the circulating tumor DNA (ctDNA) of patients with metastatic colorectal cancer and there was molecular concordance between plasmatic ctDNA and tissue samples [37,38].